Ergoteles’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Ergoteles’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,438	Closed	-$24.1K	–	1960
2022 Q4	$24.1K	Buy	+20,438	New	+$43K	﹤0.01%	1340
2022 Q3	–	Sell	-72,098	Closed	-$111K	–	2167
2022 Q2	$111K	Buy	+72,098	New	+$282K	﹤0.01%	1477
2022 Q1	–	Sell	-36,300	Closed	-$225K	–	1744
2021 Q4	$225K	Buy	+36,300	New	+$324K	0.01%	972

Other funds holding PEAR

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TAA

TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ergoteles's PEAR Position: Q1 2023 in Review

Ergoteles sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q1 2023, closing a stake of 20,438 shares — an estimated $24.1K sold.

Ergoteles first reported a position in PEAR in Q4 2021 and held it in 3 quarters. The position peaked at $225K in Q4 2021. 53 funds tracked by Wall St. Rank hold PEAR as of Q1 2023.

Ergoteles reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 20,438 Pear Therapeutics, Inc. Class A Common Stock shares in Q1 2023, an estimated $24.1K.
Ergoteles first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and held it in 3 quarters.
Ergoteles's Pear Therapeutics, Inc. Class A Common Stock position peaked at $225K in Q4 2021.
53 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.